City Research Online

City, University of London Institutional Repository

Citation: Ahamed, M. T., Forshed, J., Levitsky, A., Lehtiö, J., Bajalan, A., Pernemalm, M., Eriksson, L. E. & Andersson, B. (2024). Multiplex plasma protein assays as a diagnostic tool for lung cancer. Cancer Science, 115(10), pp. 3439-3454. doi: 10.1111/cas.16300

This is the supplemental version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: https://city-test.eprints-hosting.org/id/eprint/33464/

Link to published version: https://doi.org/10.1111/cas.16300

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

City Research Online: http://openaccess.city.ac.uk/ publications@city.ac.uk

Fig. S1:

CONSORT Flow Diagram



Fig.S1: CONSORT flow diagram. Current study utilizes the patient's data (n=670) from a cohort of patients with lung inflammatory condition (n=1200) who were referred by primary health care to Karolinska University Hospital (KUH) for investigation for suspected LC, that has been collected under the PEX-LC lung cancer investigation by Levitsky et. al., 20211 and the figure is based on CONSORT 2010 flow diagram. Out of 670 patients, blood samples of several patients (n=151) were not available for various reasons. The selection of patients to be included (n=266) for current study was not random and selected from the cohort (n=519) to suit the study accordingly. Due to logistical issues with the biobank, 253 out of 519 patients were not available for inclusion in the study. PEA has been performed on patient's blood plasma (n= 266) and medical records were retrieved. The patient cohort for current study is composed with primary LC (n=183), no cancer (n=60) and other cancer (n=23) patients, where 14 patients (n=10 in primary LC group and n=4 in no cancer group) were exclude form analysis due to missing value and not to full-fill the required data quality.

Fig. S2:



<u>Fig. S2:</u> Dataset comprising 266 samples and 92 proteins. The figure presents proteins on the x-axis, highlighting those among the 92 with the highest proportion of missing values. In this figure, the rightmost column indicates the percentage of missing values for each protein, while the adjacent columns display the count of proteins and samples showing specific levels of missingness. Notably, 12 proteins (IL5, CD28, INF beta, IL4, IL13, IL2, INF gamma, TNF, IL35, IL21, IL33, and IL1 alpha) alongside 14 patient’s sample demonstrated missing values exceeding 70% and 95%, respectively, leading to their exclusion from further analysis. Consequently, the remaining dataset consisted of 80 proteins and 252 samples, where the highest observed missing value rates were 27% for proteins and 17% for samples. To address these missing values, a replacement value of 0 was applied, following to Olink's guidelines for handling missing data.

Fig. S3:


(A)
Top 5 PC
Explained variance, %
26.6
11.1
5.62
4.43
3.7
Components
(B)
Hotelling ellipse at 95%
Comp 1 (26.56%)
Comp 2 (11.07%)
(C)
LC histology
No Cancer
nscLC_ADC
nscLC_SCC
scLC
(D)
LC stage
No Cancer
Stage I
Stage II
Stage IIIA
Stage IIIB
Stage IV
(E)
LC ordinal stage
Advance stage
Early stage
No Cancer
(F)
Gender
Female
Male
(G)
Age
25-40
41-50
51-60
61-70
71-80
81-90
(H)
Smoking status
Current smoker
Non smoke
Past smoker

Fig. S3: Principal component analysis (PCA) and 95% Hotelling ellipse to clarify the relationship between NPX values and clinical information. (A) Top 5 PC explain 51.45% of variance where top 2 together explained 37.7 % of variance, (B) Blue dotted line is the 95% Hotelling ellipse over the score plot of first 2 PC and red circle is the sample those are outside of Hotelling ellipse. The red-circled samples were retained as their inclusion or exclusion did not alter the relationship between NPX values and clinical characteristics. (C) to (H) shows the distribution of different clinical characteristics (Histology, stage, ordinal stage of LC and gender, age and smoking status of patients) on the score plot between PC1 and PC2, with none showing any clustering pattern.

Table S1:

Single protein’s performance (Confounder factor, p-value, AUC, PPV, NPV and mean expression) of patient’s group with primary LC and other cancer compared to no cancer. P values p≤0.05 are shown in grey.

Comparison groups	**Biomarkers**	**Confounder factor**	**P value adjust (Prior / post)**	**Single Biomarker**			**Mean Expression (SD)**	
				AUC	**PPV**	**NPV**	**No Cancer**	**Cancer**
Primary LC vs no cancer	**MMP12**	Age, gender	0.00 / 0.00	0.64	0.83	0.33	7.71 (0.69)	8.31 (1.26)
	CD83	-	0.01 / 0.01	0.62	0.79	0.30	2.52 (0.37)	2.35 (0.44)
	TRAIL	Age	0.01 / 0.02	0.63	0.82	0.32	8.22 (0.40)	8.05 (0.39)
	GZMB	-	0.04 / 0.04	0.58	0.78	0.29	4.41 (0.78)	3.91 (0.73)
	CD8A	Age, smoking	0.01 / 0.02	0.61	0.82	0.33	9.95 (0.75)	9.66 (0.69)
	GZMA[2]	-	0.02 / 0.02	0.59	0.77	0.27	5.67 (0.42)	5.50 (0.48)
	FASLG	Age, gender	0.02 / 0.04	0.59	0.79	0.30	5.87 (0.58)	5.65 (0.55)
	CCL19	-	0.03 / 0.03	0.60	0.80	0.30	9.78 (0.99)	9.46 (0.92)
	CD5	-	0.02 / 0.03	0.60	0.80	0.31	4.69 (0.41)	4.54 (0.41)
	CCL20	-	0.89 / 0.89	0.52	0.75	0.24	6.56 (1.19)	6.53 (1.24)
	PDL2	Gender	0.05 / 0.11	0.56	0.77	0.26	2.06 (0.39)	1.95 (0.36)
	MCP4	-	0.31 / 0.31	0.55	0.78	0.28	8.16 (0.58)	8.04 (0.74)
	MCP2	-	0.31 / 0.31	0.55	0.80	0.28	6.92 (0.66)	6.80 (0.81)
	LAMP3	-	0.81 / 0.81	0.51	0.73	0.22	4.96 (0.68)	4.93 (0.78)
	LAP_TGF_beta1	-	0.72 / 0.72	0.52	0.76	0.26	1.63 (0.40)	1.61 (0.43)
Other Cancer vs No cancer	**MMP12**	-	0.67 / 0.67	0.57	0.37	0.79	7.71 (0.69)	7.61 (1.07)
	CD83	-	0.41 / 0.41	0.57	0.30	0.73	2.52 (0.37)	2.44 (0.43)
	TRAIL	Age, smoking	0.53 / 0.78	0.55	0.34	0.76	8.22 (0.40)	8.17 (0.25)
	GZMB	Gender	0.16 / 0.20	0.59	0.32	0.74	4.41 (0.78)	3.87 (0.74)
	CD8A	-	0.08 / 0.08	0.63	0.37	0.78	9.95 (0.75)	9.62 (0.73)
	GZMA	-	0.14 / 0.14	0.62	0.37	0.79	5.67 (0.42)	5.51 (0.45)
	FASLG	Gender	0.23 / 0.18	0.56	0.31	0.73	5.87 (0.58)	5.70 (0.41)
	CCL19	-	0.12 / 0.12	0.64	0.35	0.77	9.78 (0.99)	9.39 (1.04)
	CD5	-	0.92 / 0.92	0.61	0.35	0.81	4.69 (0.41)	4.67 (0.77)
	CCL20	-	0.01 / 0.01	0.69	0.40	0.81	6.56 (1.19)	5.86 (0.54)
	PDL2	-	0.01 / 0.01	0.70	0.46	0.84	2.06 (0.39)	1.83 (0.23)
	MCP4	-	0.02 / 0.02	0.68	0.39	0.79	8.16 (0.58)	7.79 (0.72)
	MCP2	-	0.05 / 0.05	0.64	0.39	0.77	6.92 (0.66)	6.59 (0.71)
	LAMP3	-	0.03 / 0.03	0.65	0.36	0.76	4.96 (0.68)	4.58 (0.70)
	LAP_TGF_beta1	-	0.01 / 0.01	0.68	0.40	0.82	1.63 (0.40)	1.39 (0.25)

Table S2:

Single protein’s performance (Confounder factor, p-value, AUC, PPV, NPV and mean expression) of patient’s group with NSCLC and SCLC compared to no cancer. P values $p \leq 0.05$ are shown in grey.

Comparison groups	Biomarkers	Confounder factor	P value adjust (Prior / post)	Single Biomarker		
				AUC	PPV	NPV
NSCLC vs no cancer	**MMP12**	Age	0.00 / 0.02	0.63	0.81	0.35
	CD83	Smoking	0.00 / 0.00	0.63	0.78	0.32
	TRAIL	Age	0.00 / 0.02	0.63	0.80	0.33
	GZMB[2]	-	0.05 / 0.05	0.58	0.77	0.32
	CD8A	Smoking	0.02 / 0.01	0.60	0.80	0.34
	GZMA	-	0.02 / 0.02	0.59	0.76	0.29
	CD4	Age, gender	0.05 / 0.05	0.57	0.76	0.29
	CCL19	-	0.03 / 0.03	0.60	0.78	0.33
	CD5	-	0.01 / 0.01	0.61	0.79	0.33
	IL8	Age	0.07 / 0.16	0.58	0.79	0.31
	PGF	Age, gender	0.99 / 0.95	0.49	0.71	0.24
	IL12	Smoking	0.83 / 0.84	0.50	0.73	0.26
	CXCL13	-	0.29 / 0.29	0.54	0.76	0.28
	FASLG	Age, gender	0.03 / 0.07	0.59	0.77	0.31
	CAIX	Age	0.32 / 0.65	0.56	0.77	0.29
SCLC vs no cancer	**MMP12**	-	0.00 / 0.01	0.76	0.39	0.86
	CD83	-	0.71 / 0.71	0.46	0.21	0.77
	TRAIL	-	0.26 / 0.26	0.61	0.27	0.82
	GZMB	Gender	0.27 / 0.40	0.57	0.26	0.83
	CD8A	-	0.01 / 0.01	0.69	0.32	0.85
	GZMA	-	0.14 / 0.14	0.56	0.24	0.79
	CD4	-	0.93 / 0.93	0.56	0.24	0.79
	CCL19	-	0.32 / 0.32	0.56	0.23	0.79
	CD5	-	0.58 / 0.58	0.49	0.20	0.76
	IL8	Age	0.00 / 0.02	0.73	0.42	0.88
	PGF	Age, gender	0.05 / 0.02	0.60	0.29	0.82
	IL12[2]	-	0.06 / 0.06	0.60	0.31	0.85
	CXCL13	-	0.04 / 0.04	0.62	0.30	0.83
	FASLG	Gender	0.02 / 0.00	0.67	0.33	0.87
	CAIX	-	0.04 / 0.04	0.65	0.37	0.87

Table S3:

Single protein's performance (Confounder factor, p-value, AUC, PPV, NPV and mean expression) of patient's group with NSCLC, SCC and SCLC compared to no cancer. P values p≤0.05 are shown in grey.

Comparison groups	**Biomarkers**	**Confounder factor**	**P value adjust (Prior / post)**	**Single Biomarker**		
				AUC	**PPV**	**NPV**
ADC vs no cancer	**TRAIL**	Age	0.01 / 0.03	0.62	0.76	0.37
	CD8A	Age, smoking	0.01 / 0.01	0.62	0.77	0.42
	HO_1	-	0.03 / 0.03	0.59	0.72	0.35
	CD83[2]	Gender, smoking	0.00 / 0.00	0.64	0.76	0.39
	CD5	-	0.01 / 0.01	0.62	0.75	0.38
	CCL19	-	0.02 / 0.02	0.62	0.76	0.41
	FASLG	Age, gender	0.02 / 0.04	0.60	0.75	0.39
	GZMA	-	0.01 / 0.01	0.61	0.72	0.35
	MMP12	Age, smoking	0.03 / 0.18	0.60	0.74	0.37
	VEGFA	Age, gender	0.44 / 0.27	0.54	0.74	0.36
SCC vs no cancer	**TRAIL**	-	0.02 / 0.02	0.65	0.51	0.76
	CD8A	-	0.65 / 0.65	0.53	0.37	0.64
	HO_1	-	0.26 / 0.26	0.56	0.37	0.64
	CD83	-	0.22 / 0.22	0.58	0.37	0.65
	CD5	-	0.21 / 0.21	0.59	0.45	0.73
	CCL19	-	0.43 / 0.43	0.53	0.38	0.65
	FASLG	Age	0.32 / 0.64	0.54	0.36	0.64
	GZMA	-	0.53 / 0.53	0.53	0.36	0.63
	MMP12	-	0.00 / 0.00	0.74	0.60	0.80
	VEGFA	-	0.01 / 0.01	0.62	0.43	0.69
SCLC vs no cancer	**TRAIL**	-	0.26 / 0.26	0.61	0.27	0.82
	CD8A	-	0.01 / 0.01	0.69	0.32	0.85
	HO_1	Gender	0.38 / 0.16	0.60	0.26	0.82
	CD83	-	0.71 / 0.71	0.46	0.21	0.77
	CD5	-	0.58 / 0.58	0.49	0.20	0.76
	CCL19	-	0.32 / 0.32	0.56	0.23	0.79
	FASLG	Gender	0.02 / 0.00	0.67	0.33	0.87
	GZMA	-	0.14 / 0.14	0.56	0.24	0.79
	MMP12	-	0.00 / 0.00	0.76	0.39	0.86
	VEGFA	Gender	0.08 / 0.01	0.58	0.23	0.79

Table S4:

Area under ROC curve, Youden index, Sensitivity and Specificity of different cohort LC patients for panels of proteins.

		Full patient cohort	Histology based stratification				Stage based stratification										Other cancer
							Early Stage					Advanced Stage					
		PLC	NSCLC	ADC	SCC	SCLC	PLC	NSCLC	ADC	SCC	SCLC	PLC	NSCLC	ADC	SCC	SCLC	
Area under ROC curve	**Panel 1**	0.75	0.74	0.74	0.79	0.88	0.72	0.72	0.73	0.76	0.89	0.81	0.80	0.77	0.97	0.91	0.66
	Panel 2	0.57	0.57	0.58	0.56	0.64	0.61	0.60	0.62	0.54	0.81	0.64	0.65	0.63	0.75	0.55	0.57
	Panel 3	0.59	0.61	0.63	0.65	0.64	0.61	0.61	0.66	0.62	0.74	0.56	0.58	0.59	0.74	0.64	0.66
	Panel 4	0.75	0.75	0.75	0.77	0.80	0.67	0.67	0.69	0.69	0.91	0.84	0.85	0.85	0.98	0.84	0.78
	Panel 5	0.71	0.73	0.74	0.74	0.74	0.66	0.67	0.69	0.76	0.86	0.83	0.86	0.86	1.00	0.86	0.80
	Panel 6	0.60	0.60	0.60	0.66	0.64	0.64	0.65	0.65	0.70	0.80	0.63	0.63	0.61	0.77	0.69	0.80
	Panel 7	0.76	0.75	0.74	0.80	0.94	0.74	0.73	0.74	0.77	0.98	0.81	0.80	0.78	0.98	0.93	0.67
	Panel 8	0.72	0.75	0.74	0.85	0.91	0.72	0.72	0.73	0.83	0.95	0.83	0.83	0.79	1.00	0.93	0.75
	Panel 9	0.76	0.76	0.74	0.85	0.96	0.75	0.74	0.75	0.84	1.00	0.83	0.83	0.79	1.00	0.96	0.76
Youden index	**Panel 1**	36.70	35.50	34.90	42.00	51.80	31.80	33.30	27.50	41.70	80.40	46.40	42.60	40.10	91.10	69.30	21.60
	Panel 2	4.20	7.30	5.40	7.60	25.00	14.90	11.50	9.80	19.00	33.20	17.60	24.60	12.80	32.40	-7.80	16.30
	Panel 3	7.90	7.90	18.70	24.50	16.10	21.70	13.10	30.90	17.80	42.50	0.00	7.60	5.60	31.00	31.00	30.30
	Panel 4	36.10	39.00	36.50	48.70	56.20	18.70	27.60	27.40	35.10	83.90	55.00	61.40	54.50	96.40	59.90	44.60
	Panel 5	25.40	30.10	34.50	33.90	23.20	21.70	22.10	18.70	30.30	72.90	53.80	52.60	51.00	100.00	49.20	46.20
	Panel 6	15.50	15.10	12.20	21.90	14.30	22.70	20.20	22.10	15.50	46.10	20.80	27.80	16.30	27.00	17.60	49.70
	Panel 7	37.30	35.50	35.70	47.40	81.30	34.80	33.30	31.00	48.20	89.30	54.00	53.20	49.10	92.90	72.80	23.40
	Panel 8	25.20	39.60	37.50	48.70	59.80	25.20	30.70	34.60	56.60	91.10	51.00	51.00	47.30	100.00	63.50	42.80
	Panel 9	40.10	38.40	36.70	51.80	83.10	38.30	42.40	31.00	51.80	100.00	54.20	56.20	45.50	100.00	74.60	36.60
Sensitivity	**Panel 1**	0.69	0.69	0.69	0.69	0.75	0.64	0.65	0.60	0.67	1.00	0.75	0.73	0.72	1.00	0.89	0.61
	Panel 2	0.58	0.57	0.54	0.47	0.63	0.58	0.53	0.54	0.62	0.60	0.57	0.60	0.57	0.56	0.33	0.61
	Panel 3	0.56	0.56	0.62	0.66	0.63	0.66	0.58	0.70	0.57	0.80	0.50	0.54	0.56	0.67	0.67	0.70
	Panel 4	0.68	0.69	0.70	0.72	0.81	0.65	0.62	0.67	0.62	1.00	0.76	0.81	0.76	1.00	0.78	0.70
	Panel 5	0.67	0.69	0.72	0.63	0.63	0.66	0.67	0.54	0.57	0.80	0.81	0.79	0.78	1.00	0.78	0.78
	Panel 6	0.58	0.58	0.57	0.59	0.50	0.60	0.58	0.60	0.48	0.80	0.58	0.64	0.57	0.56	0.44	0.78
	Panel 7	0.69	0.69	0.70	0.69	0.94	0.69	0.65	0.61	0.71	1.00	0.74	0.75	0.76	1.00	0.89	0.61
	Panel 8	0.63	0.68	0.70	0.72	0.81	0.63	0.63	0.67	0.76	1.00	0.78	0.78	0.76	1.00	0.78	0.70
	Panel 9	0.71	0.69	0.69	0.75	0.94	0.69	0.69	0.61	0.71	1.00	0.79	0.79	0.76	1.00	0.89	0.65
Specificity	**Panel 1**	0.68	0.66	0.66	0.73	0.77	0.68	0.68	0.68	0.75	0.80	0.71	0.70	0.68	0.91	0.80	0.61
	Panel 2	0.46	0.50	0.52	0.61	0.63	0.57	0.59	0.55	0.57	0.73	0.61	0.64	0.55	0.77	0.59	0.55
	Panel 3	0.52	0.52	0.57	0.59	0.54	0.55	0.55	0.61	0.61	0.63	0.50	0.54	0.50	0.64	0.64	0.61
	Panel 4	0.68	0.70	0.66	0.77	0.75	0.54	0.66	0.61	0.73	0.84	0.79	0.80	0.79	0.96	0.82	0.75
	Panel 5	0.59	0.61	0.63	0.71	0.61	0.55	0.55	0.64	0.73	0.93	0.73	0.73	0.73	1.00	0.71	0.68
	Panel 6	0.57	0.57	0.55	0.63	0.64	0.63	0.63	0.63	0.68	0.66	0.63	0.64	0.59	0.71	0.73	0.71
	Panel 7	0.68	0.66	0.66	0.79	0.88	0.66	0.68	0.70	0.77	0.89	0.80	0.79	0.73	0.93	0.84	0.63
	Panel 8	0.63	0.71	0.68	0.77	0.79	0.63	0.68	0.68	0.80	0.91	0.73	0.73	0.71	1.00	0.86	0.73
	Panel 9	0.70	0.70	0.68	0.77	0.89	0.70	0.73	0.70	0.80	1.00	0.75	0.77	0.70	1.00	0.86	0.71

Table S5:

Area under ROC curve of different cohort of LC patients for all the panels of proteins combinedly and individually respectively.

		All	Histology based stratification				Stage based stratification										Other Cancer
							Early Stage					Advanced Stage					
		PLC	NSCLC	ADC	SCC	SCLC	PLC	NSCLC	ADC	SCC	SCLC	PLC	NSCLC	ADC	SCC	SCLC	
	Sample size (N)	**173**	**157**	**125**	**32**	**16**	**83**	**78**	**57**	**21**	**5**	**72**	**63**	**54**	**9**	**9**	**23**
P1	**Combined**	0.75	0.74	0.74	0.79	0.88	0.72	0.72	0.73	0.76	0.89	0.81	0.80	0.77	0.97	0.91	0.66
	CD83	0.62	0.63	0.64	0.58	0.54	0.60	0.60	0.62	0.54	0.64	0.64	0.64	0.65	0.62	0.58	0.57
	GZMA	0.59	0.59	0.61	0.53	0.56	0.61	0.62	0.64	0.55	0.55	0.59	0.59	0.62	0.61	0.59	0.62
	GZMB	0.58	0.58	0.57	0.61	0.57	0.63	0.64	0.63	0.66	0.50	0.47	0.48	0.52	0.52	0.66	0.59
	CD8A	0.61	0.60	0.61	0.53	0.69	0.58	0.57	0.61	0.52	0.64	0.62	0.62	0.62	0.60	0.67	0.63
	MMP12	0.64	0.63	0.60	0.74	0.76	0.58	0.57	0.54	0.65	0.68	0.69	0.68	0.64	0.91	0.76	0.57
P2	**Combined**	0.57	0.57	0.58	0.56	0.64	0.61	0.60	0.62	0.54	0.81	0.64	0.65	0.63	0.75	0.55	0.57
	CCL23	0.51	0.51	0.49	0.53	0.50	0.58	0.56	0.57	0.54	0.76	0.61	0.61	0.59	0.74	0.57	0.51
	TIE2	0.58	0.58	0.60	0.51	0.61	0.59	0.58	0.60	0.53	0.77	0.58	0.58	0.60	0.54	0.48	0.55
	CSF_1	0.54	0.54	0.56	0.54	0.51	0.60	0.60	0.62	0.53	0.67	0.54	0.54	0.49	0.71	0.56	0.57
P3	**Combined**	0.59	0.61	0.63	0.65	0.64	0.61	0.61	0.66	0.62	0.74	0.56	0.58	0.59	0.74	0.64	0.66
	Gal_9	0.56	0.56	0.56	0.57	0.50	0.59	0.58	0.60	0.53	0.71	0.52	0.53	0.51	0.65	0.54	0.58
	PDCD1	0.57	0.57	0.60	0.53	0.55	0.60	0.59	0.64	0.53	0.69	0.54	0.54	0.56	0.56	0.50	0.47
	CD4	0.56	0.57	0.59	0.49	0.44	0.56	0.56	0.61	0.56	0.58	0.46	0.56	0.56	0.53	0.43	0.61
	HO_1	0.57	0.59	0.59	0.56	0.60	0.58	0.58	0.60	0.53	0.51	0.55	0.58	0.56	0.65	0.66	0.6
P4	**Combined**	0.75	0.75	0.75	0.77	0.80	0.67	0.67	0.69	0.69	0.91	0.84	0.85	0.85	0.98	0.84	0.78
	TRAIL	0.62	0.63	0.62	0.65	0.61	0.58	0.59	0.60	0.57	0.52	0.67	0.67	0.64	0.87	0.62	0.55
	CD5	0.60	0.61	0.62	0.59	0.49	0.57	0.57	0.59	0.54	0.58	0.62	0.64	0.63	0.66	0.49	0.61
	CCL19	0.60	0.60	0.62	0.53	0.56	0.59	0.59	0.62	0.50	0.66	0.61	0.61	0.63	0.47	0.56	0.64
	FASLG	0.59	0.58	0.60	0.54	0.67	0.57	0.56	0.58	0.50	0.73	0.61	0.60	0.60	0.64	0.67	0.56
	VEGFA	0.56	0.56	0.54	0.62	0.58	0.52	0.52	0.55	0.56	0.60	0.65	0.66	0.63	0.80	0.63	0.59
	IL8	0.60	0.58	0.58	0.60	0.73	0.51	0.51	0.50	0.54	0.53	0.70	0.68	0.66	0.83	0.80	0.54
	CXCL13	0.55	0.54	0.52	0.60	0.62	0.50	0.5	0.54	0.60	0.48	0.61	0.60	0.59	0.71	0.67	0.60
	CAIX	0.56	0.56	0.54	0.60	0.65	0.56	0.56	0.55	0.59	0.47	0.56	0.55	0.53	0.65	0.66	0.60
	PGF	0.50	0.51	0.54	0.58	0.59	0.51	0.51	0.54	0.57	0.56	0.48	0.5	0.48	0.66	0.61	0.49
	IL12	0.51	0.50	0.51	0.53	0.60	0.52	0.51	0.54	0.57	0.71	0.51	0.52	0.48	0.50	0.59	0.50
P5	**Combined**	0.71	0.73	0.74	0.74	0.74	0.66	0.67	0.69	0.76	0.86	0.83	0.86	0.86	1.00	0.86	0.80
	TNFRSF12A	0.57	0.57	0.56	0.59	0.57	0.48	0.48	0.49	0.61	0.53	0.63	0.63	0.63	0.60	0.60	0.53
	MCP_3	0.55	0.56	0.54	0.60	0.54	0.49	0.49	0.54	0.56	0.54	0.64	0.65	0.64	0.72	0.55	0.49
	FGF2	0.54	0.55	0.56	0.53	0.55	0.53	0.53	0.50	0.59	0.57	0.61	0.63	0.60	0.85	0.45	0.55
	IL7	0.54	0.54	0.54	0.55	0.57	0.53	0.53	0.53	0.56	0.54	0.64	0.64	0.61	0.83	0.60	0.53
	ICOSLG	0.58	0.58	0.58	0.59	0.53	0.54	0.54	0.54	0.47	0.58	0.62	0.63	0.62	0.74	0.54	0.51
	ANG_1	0.55	0.55	0.55	0.52	0.62	0.52	0.53	0.51	0.59	0.56	0.62	0.62	0.60	0.71	0.62	0.57
	IL10	0.58	0.60	0.60	0.58	0.52	0.65	0.65	0.67	0.59	0.66	0.52	0.51	0.51	0.50	0.61	0.46
	CX3CL1	0.50	0.50	0.51	0.52	0.52	0.56	0.56	0.52	0.59	0.51	0.55	0.54	0.54	0.65	0.50	0.53
	CD244	0.55	0.55	0.56	0.52	0.51	0.55	0.55	0.55	0.56	0.54	0.56	0.57	0.59	0.57	0.54	0.50
	MMP7	0.54	0.54	0.55	0.51	0.54	0.53	0.52	0.47	0.51	0.62	0.56	0.58	0.60	0.54	0.57	0.57
	HGF	0.56	0.55	0.46	0.60	0.62	0.49	0.49	0.51	0.50	0.49	0.62	0.62	0.59	0.84	0.65	0.54
	IL6	0.52	0.52	0.51	0.64	0.49	0.55	0.45	0.59	0.57	0.63	0.60	0.61	0.57	0.84	0.54	0.57
	CD40_L	0.52	0.52	0.52	0.52	0.55	0.57	0.57	0.56	0.61	0.59	0.51	0.53	0.50	0.71	0.59	0.61
	MIC_A_B	0.52	0.53	0.56	0.57	0.62	0.52	0.52	0.54	0.53	0.48	0.49	0.52	0.57	0.74	0.73	0.53
	CXCL11	0.50	0.50	0.49	0.53	0.57	0.53	0.53	0.53	0.52	0.54	0.55	0.46	0.51	0.74	0.60	0.61
	TNFSF14	0.50	0.49	0.52	0.55	0.53	0.59	0.58	0.59	0.58	0.62	0.58	0.57	0.53	0.84	0.63	0.59
	EGF	0.51	0.49	0.52	0.53	0.51	0.56	0.56	0.53	0.63	0.49	0.55	0.56	0.54	0.69	0.52	0.59
	CASP_8	0.53	0.53	0.53	0.46	0.54	0.60	0.59	0.59	0.59	0.65	0.52	0.53	0.52	0.61	0.45	0.61
P6	**Combined**	0.60	0.60	0.60	0.66	0.64	0.64	0.65	0.65	0.70	0.80	0.63	0.63	0.61	0.77	0.69	0.80
	PD_L2	0.56	0.56	0.57	0.52	0.51	0.58	0.58	0.60	0.53	0.64	0.54	0.54	0.55	0.49	0.52	0.70
	CCL20	0.52	0.52	0.52	0.52	0.53	0.57	0.57	0.56	0.58	0.56	0.55	0.55	0.52	0.69	0.58	0.69
	MCP_4	0.55	0.55	0.55	0.56	0.58	0.58	0.58	0.59	0.57	0.54	0.54	0.52	0.53	0.48	0.64	0.68
	MCP_2	0.55	0.56	0.55	0.59	0.50	0.57	0.59	0.58	0.61	0.63	0.55	0.55	0.55	0.54	0.60	0.64
	LAMP3	0.51	0.52	0.54	0.57	0.46	0.54	0.54	0.51	0.62	0.51	0.56	0.57	0.57	0.53	0.48	0.65
	LAP TGF beta1	0.52	0.53	0.54	0.49	0.54	0.58	0.58	0.58	0.58	0.38	0.52	0.51	0.51	0.65	0.57	0.68
P7	**P1 + P2**	0.76	0.75	0.74	0.80	0.94	0.74	0.73	0.74	0.77	0.98	0.81	0.80	0.78	0.98	0.93	0.67
P8	**P1 + P3**	0.72	0.75	0.74	0.85	0.91	0.72	0.72	0.73	0.83	0.95	0.83	0.83	0.79	1.00	0.93	0.75
P9	**P1 + P2 + P3**	0.76	0.76	0.74	0.85	0.96	0.75	0.74	0.75	0.84	1.00	0.83	0.83	0.79	1.00	0.96	0.76